Jump Financial, LLC Inhibrx, Inc. Transaction History

Jump Financial, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Oct 21, 2024	BUY	$18.45 - $27.14 $470,641 - $692,314	25,509 New	25,509 $481,000
Q1 2023 May 03, 2023	SELL	$18.45 - $27.14 $140,386 - $206,508	-7,609 Reduced 22.98%	25,509 $481,000
Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $453,404 - $748,858	22,468 Added 210.97%	33,118 $816,000
Q3 2022 Nov 07, 2022	SELL	$11.58 - $24.73 $238,698 - $509,759	-20,613 Reduced 65.93%	10,650 $191,000
Q2 2022 Aug 09, 2022	BUY	$8.52 - $25.26 $72,104 - $213,775	8,463 Added 37.12%	31,263 $355,000
Q1 2022 May 12, 2022	BUY	$19.89 - $43.18 $153,153 - $332,486	7,700 Added 50.99%	22,800 $508,000
Q4 2021 Feb 10, 2022	BUY	$26.75 - $46.02 $403,925 - $694,902	15,100 New	15,100 $659,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.